Omeros’ narsoplimab headed for 1H20 submission on back of readout

Omeros is planning a follow-on offering and completion of a rolling BLA for narsoplimab after releasing the first set of pivotal data for the mAb to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, an Orphan indication with no approved therapies.

Omeros Corp. (NASDAQ:OMER) climbed $0.87 to $15.24 after reporting the data on Wednesday, before announcing that it would raise money from an existing shelf registration...